Gyre Therapeutics Amends 8-K to Include Cullgen Financials and Pro Forma Statements

summarizeSummary

Gyre Therapeutics filed an amended 8-K with audited Cullgen financials and pro forma combined statements, revealing Cullgen's Q1 2026 net loss of $8.7 million and $35.3 million in cash and investments.

check_boxKey Events · M&A and Partnerships · GYRE

• Cullgen Financials Disclosed

  Cullgen reported Q1 2026 collaboration revenue of $1.9 million, a net loss of $8.7 million, and held $35.3 million in cash and short-term investments as of March 31, 2026.

• Pro Forma Combined Results

  Pro forma combined net loss for Q1 2026 was $17.4 million, with basic loss per share of $0.16, reflecting the full consolidation of Cullgen.

• Transaction Accounting Adjustments

  The amendment details adjustments including elimination of Cullgen's preferred stock accretion and accrual of $0.3 million in additional transaction costs.

• Cash Runway Context

  Cullgen's standalone cash and investments of $35.3 million, combined with Gyre's $37.5 million, provide a combined pro forma cash position of $72.8 million as of March 31, 2026.

auto_awesomeAnalysis · GYRE · Life Sciences

For the first time since the $300 million all-stock acquisition closed on May 4, 2026, investors get a detailed look at Cullgen's financials. As of March 31, 2026, Cullgen held $35.3 million in cash and short-term investments, generated collaboration revenue of $1.9 million for Q1 2026, and posted a net loss of $8.7 million. The pro forma statements reveal the combined entity's financial position, including a pro forma net loss of $17.4 million for Q1 2026. These figures offer a clearer view of how the acquisition impacts Gyre's financials and cash runway.